Late-StageResearch compound

Trenbolone

Potent 19-nortestosterone derivative, 5x androgenic activity vs. testosterone. Aggressive on kidneys, blood pressure and prolactin; never FDA-approved for human use.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Trenbolone vial

WHAT IS TRENBOLONE?

Detailed overview

Trenbolone is a 19-norandrostene derivative originally developed for cattle muscle gain (Finaplix pellets). Anabolic:androgenic ratio 500:500, meaning 5x stronger androgenic activity than testosterone. It does not aromatize to E2, which is partly an advantage (low water retention) and partly a major drawback: progesterone-receptor activity, prolactin elevation, hypertension, renal stress (creatinine rise, eGFR drop), and severe cardiovascular burden. It has never had human FDA approval; all available Trenbolone is illegally synthesized or converted from veterinary Finaplix pellets.

Mechanism

AR agonist, no aromatization, PR activity

Anabolic:Androgenic

500:500

Half-life

3 d (Acetate), 8 d (Enanthate)

Onset

24-48 h

Legal status

No human Rx, WADA banned

Data console

Lab data

/lab/molecular-data.jsonLIVE
> Androgenic:Anabolic500:500
> AR bindingAR affinity ~5x testosterone; partial progesterone-receptor…
> Active half-life~24 h free Trenbolone (fast clearance after Ace)
> Detection windowUrinary: 4-5 months (trenbolone-glucuronide metabolite, WADA-accredited; IRMS up to 6 months).
> Aromatizationnone
> Hepatotoxicitylow-moderate

Safety

Side effects, stop signs, contraindications

Side effects · 8

  • Severe cardiovascular strain: drastic HDL drop and LDL rise, marked blood-pressure elevation, increased hematocrit, left-ventricular dysfunction with long-term use.
  • Nephrotoxicity: rising creatinine and falling eGFR reflecting partly direct renal injury (not only added muscle mass); persistent creatinine >1.4 mg/dL is a cycle-stop indication.
  • Prolactin elevation from partial progesterone-receptor agonism: gynecomastia, libido swings, erectile dysfunction, rarely lactation; standby cabergoline advised.
  • Sleep disruption and night sweats: elevated sympathetic tone and CNS stimulation cause severe insomnia and profuse night sweating in a large share of users (often 70-80%).
  • Neuropsychiatric effects: increased aggression, irritability, anxiety and mood instability; AAS dependence can also develop.
  • Strong androgenic effects: acne, increased oil production, scalp hair loss in predisposed men; in women irreversible virilization (voice deepening, hirsutism, clitoral enlargement).
  • HPTA suppression and reduced fertility: endogenous testosterone shuts down, and 19-nor metabolites can prolong spermatogenesis recovery (up to 12+ months).
  • Injection-specific effects: frequent post-injection pain (PIP) with the oil formula, plus the Trenbolone-characteristic "Tren-cough" (brief intense coughing fit after injection, especially with Acetate).

Contraindications · 7

  • Pregnancy and breastfeeding: strong androgenic-progestogenic activity, risk of fetal virilization; absolute contraindication.
  • Androgen-sensitive cancer: prostate or breast carcinoma, where androgen may stimulate tumor growth.
  • Kidney disease or impaired renal function: Trenbolone is nephrotoxic, and damage accelerates with reduced eGFR.
  • Uncontrolled hypertension or existing cardiovascular disease: Tren further raises blood pressure and worsens the lipid profile.
  • Psychiatric instability, anxiety disorder or existing sleep disturbance: Tren-aggression and insomnia aggravate these.
  • Polycythemia (hematocrit >54%): further raising hematocrit poses a thrombosis risk.
  • First AAS cycle, use without a testosterone base, or near-term plans to father a child: Tren is not a beginner compound, and 19-nor metabolites cause prolonged fertility recovery.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Trenbolone?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 19, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.